Comparison of the Incidence of Dyskinesia in Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist
NCT ID: NCT01338662
Last Updated: 2017-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2011-05-31
2022-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Is Long-term Use of Amantadine Effective in PD?
NCT04260581
Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease
NCT01538329
Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine
NCT04173832
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
NCT01227265
Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease
NCT01313845
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Prospective , randomized, open label study compare the onset time and severity of dyskinesia between groups randomized assigned order of amantadine and dopamine agonist
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A-1
* study enroll number 3n+1 (N=0,1,2...)
* initial treatment- amantadine
* add levodopa when the patient become to need further treatment.
No interventions assigned to this group
Group A-2
* study enroll number 3n+2 (N=0,1,2...)
* initial treatment: amantadine
* add dopamine agonist when the patient become to need further treatment.
No interventions assigned to this group
Group B
* study enroll number 3n+3 (N=0,1,2...)
* initial treatment: dopamine agonist
* add levodopa when the patient become to need further treatment. but cannot use amantadine
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* IPD
* H \& Y\<3
Exclusion Criteria
* dyskinesia
* Parkinson plus
* clinically significant or unstable medical or surgical condition
30 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
BS Jeon
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Beom S Jeon, MD, PhD
Role: STUDY_CHAIR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beom S Jeon
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 May 18;342(20):1484-91. doi: 10.1056/NEJM200005183422004.
Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry. 1994 Sep;57(9):1034-8. doi: 10.1136/jnnp.57.9.1034.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-1009-057-332
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.